A US-based KOL addresses the need to develop novel therapies for emerging targets of interest in ovarian cancer, especially for patients with primary platinum-refractory disease. Available treatment options across different settings are also discussed, as well as the prospects of pipeline immune checkpoint inhibitors in first-line treatment. 

This interview was conducted on 4 April 2024. 

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal. 

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.